Psilocybin
Tryp Therapeutics Raises AUD$2.4 Million
Executive Director William Garner now owns or exercises control over nearly 40% of common shares.
The post Tryp Therapeutics Raises AUD$2.4 Million appeared…
Tryp Therapeutics Inc. (CSE: TRYP) closed its previously announced private placement of secured convertible debentures for aggregate gross proceeds of AUD$ 2.4 million.
This represents an oversubscription of AUD$400,000 above its previously announced minimum placement of AUD$ 2 million. The company said the proceeds will be used to advance Tryp‘s research and development programs and for general working capital purposes.
The private placement constitutes a “related party transaction” as a director of the company has participated in the private placement, acquiring the aggregate principal amount of AUD$100,000 of debentures on the same basis as other subscribers.
Subsequent to the closing of the private placement, Dr. William Garner, executive director, owns or exercises control or direction over 38,420,000 common shares and 10,000,000 warrants, representing approximately 39.85% and 50.22% of the issued and outstanding common shares. Garner acquired an aggregate principal amount of AUD$1,200,000 of debentures under the private placement.
This assumes that the debentures convert at a price of CDN$0.09/share, 64.05% of the issued and outstanding common shares on a partially diluted basis and that Garner exercised all of his warrants and converted all of his debentures and no other holders of convertible securities exercised or converted any of their securities.
This same director is entitled to receive certain fees from Westar Capital Ltd., which acted as lead manager for the private placement, in connection with the private placement and the transactions contemplated in the engagement agreement.
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. Tryp’s lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) that alleviates numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
The post Tryp Therapeutics Raises AUD$2.4 Million appeared first on Green Market Report.
psilocybin psychedelic therapeutics psychotherapy private placement shares cse capital tryp therapeutics tryp research-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment